Stereotactic radiotherapy (SBRT/SRS)

What it is

Stereotactic radiotherapy (SBRT/SRS) is a precise form of radiation therapy that delivers high doses of radiation to small, well-defined tumors or metastases. It uses advanced technology to target the tumor with minimal exposure to surrounding healthy tissue.

What research shows

Studies suggest that SBRT/SRS can achieve high local control rates and favorable outcomes in various cancer types, including prostate, lung, liver, and brain cancers. For example, a European multicenter cohort study found that SBRT for bone oligometastases from breast cancer resulted in favorable oncological outcomes. However, more research is needed to establish optimal treatment protocols and to identify predictive factors of response.

Current status

SBRT/SRS is a valuable treatment option for patients with limited metastatic disease or small, localized tumors. However, its use is limited by the need for precise targeting and the potential for radiation-induced side effects, particularly in previously irradiated areas.

Key studies

• PMID 41853739

  A European multicenter cohort study found that stereotactic body radiotherapy (SBRT) for bone oligometastases from breast cancer resulted in favorable oncological outcomes.

  PubMed ↗
• PMID 41864432

  The CYGNUS study aimed to assess the efficacy and toxicity of stereotactic body radiotherapy (SBRT) as a salvage approach for pelvic nodal metachronous oligorecurrent prostate cancer.

  PubMed ↗
• PMID 41858132

  A retrospective single-center cohort study found that concurrent immunotherapy was associated with increased radiation necrosis risk in lung cancer patients with brain metastases treated with stereotactic radiosurgery.

  PubMed ↗